On Monday, Oppenheimer initiated coverage on shares of Penumbra (NYSE:PEN), a medical device company, with an Outperform rating and a price target of $275. Currently trading at $247.24, InvestingPro data shows the company maintains excellent financial health with a "GREAT" overall score.
The firm recognizes Penumbra as a leading entity in the mechanical thrombectomy (MT) market, citing a diverse product range that addresses various medical conditions including deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, and arterial issues.
The firm forecasts robust mid-teens sales growth for Penumbra, along with an over 30% increase in earnings per share (EPS) moving forward. This outlook aligns with the company's strong performance, as evidenced by its 17% revenue growth over the last twelve months and healthy gross profit margin of 63%.
This optimistic outlook is based on anticipated market share gains within the expanding core MT markets, international expansion of Penumbra's proprietary CATV thrombectomy technology, and the launch of new products. Among these new offerings is the next-generation Thunderbolt system for treating ischemic stroke, expected to be introduced in 2025.
The analyst also points to the potential pipeline contributions as a factor that could provide additional upside to their estimates. This includes the greater contribution from the Thunderbolt system, for which the firm currently holds conservative forecasts.
In other recent news, Penumbra has experienced significant developments. The medical device company's stock was upgraded from Equal Weight to Overweight by Wells Fargo (NYSE:WFC), following optimism over the success of the THUNDER trial. Wells Fargo anticipates successful outcomes for the trial and a promising market introduction of Thunderbolt in 2025.
The company also reported a substantial increase in Q3/24 revenue, driven by a robust performance in the U.S. thrombectomy sector. The revenue reached $301.0 million, marking an 11.1% year-over-year increase.
In addition, Penumbra revealed data indicating that its computer assisted vacuum thrombectomy (CAVT™) technology reduces hospital stays and complications for patients with intermediate-risk pulmonary embolism. The study showed that treatment with Penumbra's CAVT resulted in 25-35% shorter hospital stays and significantly reduced complications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.